Tekla Life Sciences Investors HQL | NYSE
Company Overview:
10 Year HQL Performance Metrics:
HQL Dividend Charts
Build Custom Charts
HQL Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
HQL Dividends Info:
Projected Future Returns & Dividends for HQL
Based on past 10-year performance, here are HQL growth metrics:
Share price CAGR of -0.44%
Dividend CAGR of +3.51%
Using HQL CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| HQL (DRIP) | HQL - No DRIP | |
|---|---|---|
| Current Price | $18.01 | $18.01 |
| Start Shares | 555.25 | 555.25 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 2,798.00 | 555.25 |
| Dividends Payment | $0.88 | $0.88 |
| Annual Dividends | $9,799 | $1,945 |
| Yield on cost | 97.99% | 19.45% |
| Share Price | $17.23 | $17.23 |
| Total Dividends | $39,330 | $16,163 |
| Final Value | $48,223 | $25,732 |
NOTE: Above numbers are our estimate based on HQL's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Tekla Life Sciences Investors (HQL) had its IPO on 1992-05-01, and is traded on NYSE stock exchange.
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
HQL website: http://www.abrdnhql.com
DCF Model — HQL
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
